Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)
Treatment with upadacitinib achieved both ClinRO and PRO optimal treatment targets as well as MDA and may optimize overall disease management in patients with moderate-to-severe AD.
Authors
- Melinda Gooderham (ORCID: https://orcid.org/0000-0001-8926-0113)
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Wan‐Ju Annabelle Lee (ORCID: https://orcid.org/0000-0002-9972-8899)
- Andrew Pink (ORCID: https://orcid.org/0000-0001-5151-5539)
- Valéria Aoki (ORCID: https://orcid.org/0000-0003-4256-4413)
- Yousef Binamer (ORCID: https://orcid.org/0000-0003-0948-7102)
- Brian Calimlim (ORCID: https://orcid.org/0000-0002-6463-6433)
- Petra Staubach (ORCID: https://orcid.org/0000-0002-2276-0284)
- Alvaro Moreira (ORCID: https://orcid.org/0000-0002-5244-9286)
- Ayman Grada (ORCID: https://orcid.org/0000-0002-5321-0584)
- Chao Li (ORCID: https://orcid.org/0000-0001-5723-1414)
- Andreas Wollenberg
- Brad Glick
- Norito Katoh
Institutions
- Universidade de São Paulo (BR)
- George Washington University (US)
- Johannes Gutenberg University Mainz (DE)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Queen's University (CA)
- King Faisal Specialist Hospital & Research Centre (SA)
- University Hospital Augsburg (DE)
- AbbVie (United States) (US)
- Kyoto Prefectural University of Medicine (JP)
- SKiN Health (CA)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Probity Medical Research (CA)
- Clinical Pharmacology of Miami (US)
- Trent University (CA)
- Ludwig-Maximilians-Universität München (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1007/s13555-025-01485-0
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00
Funders
- AbbVie